Clinical use and the Italian demand for prothrombin complex concentrates

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Franchini, Massimo ^a   Liumbruno, Giancarlo M ^b   Lanzoni, Monica ^c,d   Candura, Fabio ^c   Vaglio, Stefania ^c,e   Profili, Samantha ^c   Facco, Giuseppina ^c,f   Calizzani, Gabriele ^c   Grazzini, Giuliano ^c  

^a CARLO POMA HOSPITAL   (Italy)

^b SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Dermatopathology Section Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

Author keywords

Inherited clotting factor deficiency; Plasma derived medicinal products; Prothrombin complex concentrates; Prothrombin complex congenital deficiency; Vitamin K antagonist reversal

Indexed keywords

PRONATIV; PROTHROMBIN COMPLEX; PROTROMPLEX; UMANCOMPLEX; UNCLASSIFIED DRUG;

BLOOD CLOTTING FACTOR 10 DEFICIENCY; COMPARATIVE STUDY; DRUG INDICATION; DRUG USE; GEOGRAPHIC DISTRIBUTION; HEMOPHILIA B; HUMAN; ITALY; PROTHROMBIN DEFICIENCY; REVIEW;

BLOOD COAGULATION FACTORS; HUMANS; ITALY;

EID: 84885574861     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.015s     Document Type: Review

References (32)

1. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10. (Pubitemid 30113894)
2. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999; 95: S7-12.
3. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8: 149-54.
4. Legislative Decree 219/2006. "Implementation of Directive 2001/83/EC (and subsequent amendment directives) on a Community code relating to medicines for human use, as well as Directive 2003/94/EC". Available at: http://www.agenziafarmaco.gov.it/it/content/normativa-di- riferimentoregistrazione. Accessed on 13/08/2013.
5. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 2006; 91: 634-9. (Pubitemid 43799459)
6. Rodgers GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012; 87: 898-902.
7. Società Italiana di Medicina Trasfusionale e Immunoematologia. Raccomandazioni SIMTI sul corretto utilizzo degli emocomponenti e dei plasmaderivati. Milano: Edizioni SIMTI; 2008.
8. Hellstern P, Halbmayer WM, Kohler M, et al. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 1999; 95: S3-6. (Pubitemid 29461041)
9. Liumbruno G, Bennardello F, Lattanzio A, et al. on behalf the Italian Society of Transfusion Medicine and Immunohematology (SIMTI). Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009; 7: 325-34.
10. Sorensen B, Spahn DR, Innerhofer P, et al. Clinical review: protrhombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201.
11. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48. (Pubitemid 44881256)
12. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-43.
13. Baglin T, Keeling DM, Watson HG; British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006; 132: 277-85. (Pubitemid 43381534)
14. Dentali F, Ageno W, Crowther M. Treatment of coumarinassociated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853-63. (Pubitemid 44226758)
15. Viguè B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009; 13: 209.
16. Pernod G, Godiér A, Gozalo C, et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126: e167-74.
17. Keeling D, Baglin T, Tait C, et al. British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154: 311-24.
18. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e152S-84S.
19. Makris M, Van Veen JJ, Tait CR, et al.; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160: 35-46.
20. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organization. Haemophilia 2004: 10: 593-628. (Pubitemid 39317772)
21. Acharya SS, Coughlin A, Dimichele DM; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-56. (Pubitemid 40186038)
22. Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrate with two virus inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15: 15-20. (Pubitemid 36135657)
23. Lanzoni M, Biffoli C, Candura F, et al. Plasma-derived medicinal products in Italy: information sources and flows. Blood Transfus 2013; 11 (Suppl 4): s13-7.
24. Calizzani G, Lanzoni M, Candura F, et al. Analisi della Domanda dei Principali Medicinali Plasmaderivati in Italia. Anni 2007-2011. Roma: Istituto Superiore di Sanità 2012. (Rapporti ISTISAN 12/53). Available at: http://www.iss.it/binary/publ/cont/dodici53web.pdf. Accessed on 24/08/2012.
25. Robert P; The Marketing Research Bureau (MRB). The Worldwide Plasma Fractions Market 2008. April 2010 Ed. Orange, CT: The Marketing Research Bureau, Inc.; 2010.
26. Degos V, Westbroek EM, Lawton MT, et al. Perioperative Management of Coagulation in Nontraumatic Intracerebral Hemorrhage. Anesthesiology 2013; 119: 218-27.
27. Morgenstern LB, Hemphill JC III, Anderson C, et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-29.
28. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944-82.
29. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382.
30. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; DOI 10.2450/2013.0029-13.
31. Tran HA, Chunilal SD, Harper PL, et al. An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198: 198-9.
32. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.